Use of misoprostol before tandem application for intracavitary brachytherapy in patients of carcinoma cervix: An institution study.
J Cancer Res Ther
; 18(6): 1569-1571, 2022.
Article
en En
| MEDLINE
| ID: mdl-36412412
ABSTRACT
Aim:
To investigate the ease of tandem application and external os identification by giving sublingual misoprostol before initiation of intracavitary brachytherapy in cancer cervix patients. Materials andMethods:
36 patients with cervical cancer stage IIIB which were supposed to undergo intracavitary brachytherapy(ICBT) were randomly divided into 2 subgroups, group A patients receiving misoprostol and group B not receiving misoprostol.Misoprostol 400 mcg was given sublingually 3 hrs prior to the procedure. The efficacy of the drug was measured as per the ease of identification of os and easier tandem application and amount of bleeding during procedure.Results:
Application of tandem and identification of external os was easier and amount of bleeding was also less in patients that were administered sublingual misoprostol.Conclusion:
Sublingual Misoprostol given before ICBT helps in cervical ripening and thus leads to easier os recognition and central tandem application and reduce overall anaesthesia time.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Braquiterapia
/
Carcinoma
/
Neoplasias del Cuello Uterino
/
Misoprostol
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
J Cancer Res Ther
Asunto de la revista:
NEOPLASIAS
/
TERAPEUTICA
Año:
2022
Tipo del documento:
Article
País de afiliación:
India